Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHSE:688576's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.64 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Chongqing Xishan Science and Technology Co Debt-to-EBITDA Related Terms
Chongqing Xishan Science and Technology Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Xishan Science and Technology Co Debt-to-EBITDA Chart
Chongqing Xishan Science and Technology Co Annual Data
SHSE:688576 vs ISRG, BDX, RMD: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Chongqing Xishan Science and Technology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Xishan Science and Technology Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chongqing Xishan Science and Technology Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chongqing Xishan Science and Technology Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Chongqing Xishan Science and Technology Co (SHSE:688576) has a Debt-to-EBITDA of 0.25 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Chongqing Xishan Science and Technology Co. This is 1150% above median its historical median of 0.02. According to the industry distribution chart, Chongqing Xishan Science and Technology Co ranks #999999 out of 471 companies in the Medical Devices & Instruments industry.
Is Chongqing Xishan Science and Technology Co's Debt-to-EBITDA too high?
Chongqing Xishan Science and Technology Co's current Debt-to-EBITDA of 0.25 is 1150% above median its 10-year median of 0.02. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Chongqing Xishan Science and Technology Co's value of 0.25 is 84.8% below this industry median. Based on the distribution chart, Chongqing Xishan Science and Technology Co ranks #999999 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Chongqing Xishan Science and Technology Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chongqing Xishan Science and Technology Co's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Chongqing Xishan Science and Technology Co ranks #999999 out of 471 companies for Debt-to-EBITDA. This places Chongqing Xishan Science and Technology Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Chongqing Xishan Science and Technology Co's value of 0.25 is 84.8% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 1.64, Chongqing Xishan Science and Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chongqing Xishan Science and Technology Co's current Debt-to-EBITDA of 0.25 is 84.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Chongqing Xishan Science and Technology Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chongqing Xishan Science and Technology Co's current Debt-to-EBITDA is 0.25, which is 1150% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Xishan Science and Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Chongqing Xishan Science and Technology Co (SHSE:688576) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥49.38, compared to a current price of ¥38.46 — trading 22.1% below its estimated fair value. The current Debt-to-EBITDA is 0.25, which is 1150% above median its 10-year median of 0.02 and 84.8% below the Medical Devices & Instruments industry median of 1.64. Chongqing Xishan Science and Technology Co's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Chongqing Xishan Science and Technology Co (SHSE:688576), the current Debt-to-EBITDA is 0.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chongqing Xishan Science and Technology Co (SHSE:688576) Overvalued in 2026?
Based on GuruFocus' analysis, Chongqing Xishan Science and Technology Co stock appears to be undervalued.
The current stock price of ¥38.46 is trading 22.1% below its estimated GF Value™ of ¥49.38.
GuruFocus considers Chongqing Xishan Science and Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688576:
Debt-to-EBITDA: 0.25 (1150% above median its 10-year median of 0.02)
GF Value™: ¥49.38 vs. price of ¥38.46 (22.1% below fair value)
Industry Position: 84.8% below the Medical Devices & Instruments median (#999999 of 471)
No single metric tells the full story. See the SHSE:688576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressNo. 9, Middle Section of Huangshan Avenue, Jupiter Science and Technology Development Center, High-tech Park, North New District, Chongqing, CHN, 401121
Chongqing Xishan Science and Technology Co Ltd focuses on surgical instruments, especially in the field of minimally invasive surgical instruments. It is mainly engaged in the research, development, production and sales of minimally invasive surgical instruments. Speculum, energy surgery equipment and other products, currently the products are mainly used in neurosurgery, ENT, orthopedics, breast surgery and other clinical departments. The company's main products are surgical power units, consumables and accessories, which are mainly used for cutting, grinding, planing, sawing, milling and trimming of bone tissue and soft tissue in surgical operations, especially minimally invasive surgical operations.
90GF Score
Get the complete analysis for SHSE:688576
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688576 has been successfully added to your 
